MONTREAL, July 18 /CNW Telbec/ - Generations of Canadians have suffered from diseases caused by the human papillomavirus (HPV) - the most known of these being cervical cancer. Today, Merck Frosst announces that GARDASIL(TM), its quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, has been approved by Health Canada for females between nine and 26 years of age for the prevention of cervical cancer, vulvar cancer, vaginal cancer, precancerous lesions and genital warts caused by the vaccine HPV types. A first of its kind in Canada, the vaccine will be available by the end of August 2006 through Canadian physicians and pharmacists.
